Abstract Library

#4304 Co-targeting the Endocannabinoid System (ES) and mTOR in NEN potentiates their anti-tumour effect via unique metabolic changes

Introduction: The current treatment of neuroendocrine neoplasms (NEN) has limited efficacy, highlighting the need for novel therapeutic approaches. We have previously shown the potential therapeutic benefit when combining ES blocking with Everolimus (Eve).

Conference:

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Kogot-Levin A, Abramovich I, Agranovich B, Polak D,

Keywords: Neuroendocrine neoplasm, Endocannabinoid system, Everolimus, metabolic Changes, metabolomics,

#4257 Tolerability and outcomes of neuroendocrine tumors treated with peptide receptor radionuclide therapy and stereotactic body radiation therapy

Introduction: The addition of stereotactic body radiation therapy (SBRT) to patients treated with PRRT may provide synergistic benefit by targeting specific sites of disease that represent areas of tumor heterogeneity. Little is known regarding the efficacy or potential toxicity of this approach. A retrospective review of patients with NEN treated with sequential PRRT and SBRT was performed to provide preliminary outcome and toxicity data to inform further combined treatment strategies.

Conference:

Presenting Author: Myrehaug S

Authors: Nunez Rodriguez J, Ng S, Chen H, Singh S, Hallet J,

Keywords: PRRT, Radiation, SABR, SBRT,

#4216 Immunohistochemical analysis for galectin-3 and outcomes in medullary thyroid cancer

Introduction: Galectin-3 (Gal-3) is a beta-galactoside involved in multiple biological and pathological processes including growth and differentiation, cellular adhesion and transformation, and metastatic potential.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Giampietro A, Lugli F, Maratta M,

Keywords: Thyroid, MTC, Galectine3,

#4141 BRAF/MEK combination treatment in a patient with BRAF mutated neuroendocrine carcinoma

Introduction: Preclinical studies indicate that BRAF V600E mutation is a druggable target in neuroendocrine carcinomas (NEC). Indeed, there are a few case reports that describe clinical response from BRAF inhibitor treatment of colorectal NEC.

Conference:

Presenting Author: Zhang L

Authors: Falkman L, Zhang L, Welin S, Crona J,

Keywords: Neuroendocrine carcinoma, BRAF V600E, Dabrafenib, Trametinib,

#3818 Somatostatin analogues or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors

Introduction: Non-functioning (NF), sporadic, G1-G2 pancreatic neuroendocrine tumors (PanNETs) usually display an indolent course. Surgery is the first-choice treatment for localized tumors >2 cm. Unresectable or metastatic PanNETs expressing somatostatin receptors (SSTRs) are treated with somatostatin analogues (SSAs). The PROMID and the CLARINET studies proved the SSA antiproliferative effect in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The standard treatment for patients with PanNETs ≤2cm is active surveillance (AS). Yet no evidence of the value of SSA treatment exist in such patient population.

Conference:

Presenting Author: Maratta M

Authors: Maratta M, Chiloiro S, Raia S, Maiorano B, Rossi E,

Keywords: PanNET, somatostatin analogues, efficacy, surveillance, medical treatment,